Foseco India Ltd
FOSECOINDFoseco India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 11 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (11 weeks in). Underneath, the last four quarters read mixed, and 95% of the last 2 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Foseco India Ltd trades at ₹6,195, in a confirmed uptrend and 11 weeks into that stage. That is +19.3% against its own 200-day average. It sits at 92% of a 52-week range of ₹4,386 to ₹6,362. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a confirmed uptrend — week 11 of stage 2, confirmed. At ₹6,195 it trades +19.3% versus its 200-day average and sits at 92% of its 52-week range (₹4,386–₹6,362).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +428% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Foseco India Ltd trades at 44.8× P/E, against too little history to rank. Its long-run median P/E is 43.8×, measured across 0.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 44.8× is against too little history to rank, against a long-run median of 43.8× measured over 0.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −16.1% against a +1.4% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Foseco India Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 15.9% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +22.5% | — | — | — |
| Profit | +2.7% | — | — | — |
| EPS | −16.1% | — | — | — |
| Share price | +1.4% | +20.6% | +32.8% | +15.8% |
4-Factor Sector Score
63.1/100 — rank 2 of 20 in Chemicals - Organic · 87% evidence confidence
Foseco India Ltd scores 63.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19.5 + 16.9 + 11.5 + 15.2 = 63.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Foseco India Ltd reported ₹231 Cr of revenue in the Jun 26 quarter. Over 1 years it has compounded at 22.5% a year. The last full year, FY25, came in at ₹643 Cr. The last four reported quarters add to ₹773 Cr.
FY25 revenue came in at ₹643 Cr (+22.5% on the year), capping 1 years at 22.5% compound. The latest quarter (Jun 26) printed ₹231 Cr, null year on year.
Pace check: the last four quarters averaged +27.2% growth against the decade's 22.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +40.3% over the last 4 quarters against +25.7%/yr over the last 8 — accelerating; TTM profit +25.0% vs +15.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Foseco India Ltd's operating margin is 23.0% in the Jun 26 quarter. Across the last four quarters the operating margin has moved +5.0 percentage points.
The latest quarter's operating margin is 23.0%, null pp against the same quarter a year ago. Across 2 fiscal years the operating margin has ranged 17.0%–19.0%.
Why the margin moved: operating margin went +5.2 pp year on year while gross margin went +6.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Foseco India Ltd earned ₹36.0 Cr of net profit in the Jun 26 quarter. Full-year FY25 profit was ₹75.0 Cr. The 1-year compound rate is 2.7%. That is 15.6% of the quarter's revenue. The same quarter a year earlier earned ₹22.0 Cr.
Jun 26 profit was ₹36.0 Cr, null year on year. On the full year, FY25 printed ₹75.0 Cr (+2.7%), and the 1-year compound rate is 2.7%.
Pace comparison, last four quarters: profit +3.1% vs revenue +27.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 95% of Foseco India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹98.0 Cr of operating cash against ₹75.0 Cr of profit. After ₹744 Cr of capital spending, ₹−646 Cr was left as free cash.
FY25: operating cash of ₹98.0 Cr against reported profit of ₹75.0 Cr, leaving free cash of ₹−646 Cr after ₹744 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 95% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 95%: the cash cycle held roughly steady between FY24 and FY25 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 57.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Foseco India Ltd's cash conversion cycle runs −22 days in FY25, down from −22 days in FY24. Capital spending ran ₹744 Cr over the last 1 years. At FY25 sales of ₹643 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹−39.0 Cr sits inside the business at any moment.
FY25: debtors at 87 days, inventory at 57 days — roughly 1.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −22 days, tighter than FY24's −22.
The full loop: cash goes out to suppliers and production on day 0; stock waits 57 days to sell; customers pay about 87 days after that; and suppliers themselves are paid at 166 days — netting out to the −22-day cycle.
In money terms: at FY25 sales of ₹643 Cr, each day of the cycle holds about ₹1.8 Cr — so the −22-day loop keeps roughly ₹−39.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹744 Cr over the last 1 fiscal years against ₹13.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹4.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Foseco India Ltd earns a ROCE of 17% in FY25. Return on invested capital clears the cost of that capital by +0.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.7% net margin on 0.47× asset turns.
FY25 ROCE is 17%.
Why the return is what it is — the wiring (FY25): 11.7% net margin × 0.47× asset turns × 1.32× balance-sheet leverage ≈ 7.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 12.8% − 12.0% = a +0.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Foseco India Ltd carries total debt of ₹3.0 Cr against shareholder equity of ₹1,120 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY24 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹3.0 Cr against shareholder equity of ₹1,120 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY24) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 11.4 points of Foseco India Ltd over 8 quarters, the biggest move on the register. That takes promoters to 63.5% of the company. Domestic institutions moved +0.2 points over the same window, to 0.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −11.4 points over 8 quarters to 63.5%; Domestic institutions: +0.2 points over 8 quarters to 0.4%; Foreign institutions: −0.1 points over 8 quarters to 0.1%.
🚨 Why the register moved: promoters drove it (−11.4 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Foseco India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Valiant Organics LtdVALIANTORG | 63.2/100Mixed-positive evidence87% evidence | TURNING | 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence | 10.8/25 ROCE 5.5% · OPM 18% 95% evidence | 11.0/20 P/E 22× · PEG — 50% evidence | 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Foseco India Ltdthis pageFOSECOIND | 63.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence | 16.9/25 ROCE 17.4% · OPM 23% 100% evidence | 11.5/20 P/E 44.8× · PEG 1.31 65% evidence | 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elantas Beck India LtdELANTAS | 62.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence | 19.1/25 ROCE 21.2% · OPM 29% 76% evidence | 6.3/20 P/E 64.8× · PEG — 50% evidence | 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence |
| Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4OCCL LtdOCCLLTD | 61.4/100Mixed-positive evidence60% evidence | BREAKING OUT | 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.2/25 ROCE 13% · OPM 28% 76% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shri Ahimsa Naturals LtdSHRIAHIMSA | 61.0/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 18.0/25 ROCE 21.7% · OPM 28% 95% evidence | 10.0/20 P/E 37.2× · PEG — 15% evidence | 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Indo Amines LtdINDOAMIN | 60.6/100Mixed-positive evidence81% evidence | BASING | 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence | 16.8/25 ROCE 19.9% · OPM 14% 95% evidence | 14.0/20 P/E 11.3× · PEG — 50% evidence | 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Balaji Amines LtdBALAMINES | 59.3/100Mixed-positive evidence82% evidence | LEADER | 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.3/25 ROCE 11% · OPM 25% 76% evidence | 7.0/20 P/E 36.1× · PEG — 50% evidence | 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nitta Gelatin India LtdNITTAGELA | 59.2/100Mixed-positive evidence72% evidence | TURNING | 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence | 19.1/25 ROCE 27.7% · OPM 24% 95% evidence | 9.7/20 P/E 14.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence |
| Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9BASF India LtdBASF | 52.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence | 10.7/25 ROCE 14.5% · OPM 10% 100% evidence | 14.3/20 P/E 25.7× · PEG 1.62 100% evidence | 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GFL LtdGFLLIMITED | 51.5/100Mixed-positive evidence72% evidence | BREAKING OUT | 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence | 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Laxmi Organic Industries LtdLXCHEM | 49.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.4/25 ROCE 4.7% · OPM 12% 100% evidence | 14.7/20 P/E 38.8× · PEG 1.14 100% evidence | 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 45.6/100Mixed-negative evidence100% evidence | BREAKING OUT | 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence | 17.6/25 ROCE 21.5% · OPM 25% 100% evidence | 7.2/20 P/E 36.2× · PEG 2.7 100% evidence | 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jyoti Resins and Adhesives LtdJYOTIRES | 43.1/100Mixed-negative evidence69% evidence | 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence | 19.2/25 ROCE 36.5% · OPM 14% 76% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sigachi Industries LtdSIGACHI | 41.5/100Mixed-negative evidence79% evidence | BREAKING OUT | 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence | 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence | 8.4/20 P/E 64.5× · PEG — 50% evidence | 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Shree Ganesh Remedies LtdSGRL | 41.1/100Mixed-negative evidence76% evidence | 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence | 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence | 7.1/20 P/E 54.8× · PEG — 50% evidence | 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Oriental Aromatics LtdOAL | 36.0/100Mixed-negative evidence74% evidence | BREAKING OUT | 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 337× · PEG — 15% evidence | 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Fairchem Organics LtdFAIRCHEMOR | 33.6/100Adverse evidence87% evidence | BREAKING OUT | 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 6.0/25 ROCE 3.3% · OPM 10% 95% evidence | 8.0/20 P/E 52× · PEG — 50% evidence | 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Gem Aromatics LtdGEMAROMA | 24.4/100Adverse evidence65% evidence | ASLEEP | 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence | 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence | 8.5/20 P/E 772.2× · PEG — 15% evidence | 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Sacheerome LtdSACHEEROME | 59.1/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.3/25 ROCE 35.7% · OPM 23% 95% evidence | 9.7/20 P/E 40.1× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence |
| Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 36.7/100Thin evidence · provisional27% evidence | 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence | 4.9/25 ROCE -2150% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Foseco India Ltd's share price today?
Foseco India Ltd trades at ₹6,195, +1.4% over the past year. The company is valued at ₹4,669 Cr. The stock sits at 92% of its 52-week range of ₹4,386–₹6,362, +19.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 11 weeks in. — as of 11 September 2026.
What were Foseco India Ltd's latest quarterly results?
Foseco India Ltd reported revenue of ₹231 Cr and net profit of ₹36.0 Cr for the Jun 26 quarter. Earnings per share were ₹44.74. The operating margin was 23.0%. — as of 11 September 2026.
What is Foseco India Ltd's revenue?
Foseco India Ltd reported revenue of ₹231 Cr in the Jun 26 quarter. For the full FY25 fiscal year, revenue was ₹643 Cr (+22.5%). Over the last 1 years revenue compounded at 22.5% a year. — as of 11 September 2026.
What is Foseco India Ltd's profit?
Foseco India Ltd earned ₹36.0 Cr of net profit in the Jun 26 quarter. Full-year FY25 profit was ₹75.0 Cr. The operating margin ran 23.0% in the latest quarter. — as of 11 September 2026.
What is Foseco India Ltd's market cap?
Foseco India Ltd's market capitalisation is ₹4,669 Cr at a share price of ₹6,195. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
Does Foseco India Ltd pay a dividend?
Yes — Foseco India Ltd's dividend payout was 26% of profit in FY25, and it recorded a payout in each of its last 2 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
How is Foseco India Ltd performing?
Foseco India Ltd is in a confirmed uptrend, 11 weeks in. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Foseco India Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 15.9% and holding. The read comes from the last 12 quarters of growth (revenue growth +40.3% latest, profit growth +25.0% latest, eps growth +4.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Foseco India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 11 of stage 2), trading +19.3% versus its 200-day average and at 92% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Foseco India Ltd beating the market?
On recent form, yes — Foseco India Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +428% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Foseco India Ltd's share price go up?
This page publishes no price forecast for Foseco India Ltd. What it measures instead: the share price is ₹6,195, the price is in a confirmed uptrend 11 weeks in. Direction is not something this site claims to know. — as of 11 September 2026.
Who owns Foseco India Ltd?
Promoters hold 63.5% of Foseco India Ltd, foreign institutions 0.1%, domestic institutions 0.4% and the public 36.0% (latest quarter). The biggest move on the register over the last two years: Promoters cut 11.4 points over 8 quarters. — as of 11 September 2026.
Does Foseco India Ltd have too much debt?
No — Foseco India Ltd's debt-to-equity is 0.00. FY25 borrowings were ₹3.0 Cr against equity of ₹1,037 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Foseco India Ltd's capex?
Foseco India Ltd spent ₹744 Cr on capital expenditure over the last 1 fiscal year, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹744 Cr, with ₹4.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Foseco India Ltd's cash flow?
Foseco India Ltd generated ₹98.0 Cr of operating cash flow in FY25 and ₹−646 Cr of free cash flow after ₹744 Cr of capital spending. Reported profit that year was ₹75.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Foseco India Ltd's profit real cash?
Yes — over the last 2 fiscal years, 95% of Foseco India Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹98.0 Cr against reported profit of ₹75.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Foseco India Ltd in its business cycle?
Foseco India Ltd's FY25 operating margin was 19.0%, against a 2-year band of 17.0%–19.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 23.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Foseco India Ltd story?
Biggest watch item: the price is already 11 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Foseco India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Foseco India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!